141 related articles for article (PubMed ID: 7858496)
21. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
[TBL] [Abstract][Full Text] [Related]
22. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Hatzimichael E; Dasoula A; Shah R; Syed N; Papoudou-Bai A; Coley HM; Dranitsaris G; Bourantas KL; Stebbing J; Crook T
Eur J Haematol; 2010 Jan; 84(1):47-51. PubMed ID: 19737309
[TBL] [Abstract][Full Text] [Related]
23. Lack of BCL10 mutations in multiple myeloma and plasma cell leukemia.
Shih LY; Fu JF; Shurtleff SA; Morris SW; Downing JR
Genes Chromosomes Cancer; 2001 Apr; 30(4):402-6. PubMed ID: 11241793
[TBL] [Abstract][Full Text] [Related]
24. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Chim CS; Liang R; Leung MH; Kwong YL
J Clin Pathol; 2007 Jan; 60(1):104-6. PubMed ID: 17213358
[TBL] [Abstract][Full Text] [Related]
25. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
27. A high frequency of N-RAS oncogene mutations in multiple myeloma.
Tanaka K; Takechi M; Asaoku H; Dohy H; Kamada N
Int J Hematol; 1992 Oct; 56(2):119-27. PubMed ID: 1421173
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Bataille R; Jourdan M; Zhang XG; Klein B
J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
[TBL] [Abstract][Full Text] [Related]
29. p53 and RAS gene mutations in multiple myeloma.
Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
[TBL] [Abstract][Full Text] [Related]
30. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients.
Span M; Moerkerk PT; De Goeij AF; Arends JW
Int J Cancer; 1996 Jun; 69(3):241-5. PubMed ID: 8682594
[TBL] [Abstract][Full Text] [Related]
31. Promoter methylation of the bone morphogenetic protein 6 gene in multiple myeloma.
Hashida Y; Nemoto Y; Imajoh M; Murakami M; Taniguchi A; Komatsu N; Yokoyama A; Daibata M
Oncol Rep; 2012 Mar; 27(3):825-30. PubMed ID: 22086350
[TBL] [Abstract][Full Text] [Related]
32. N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma.
Ortega MM; Faria RM; Shitara ES; Assis AM; Albuquerque DM; Oliveira JS; Noguti MA; Faria JR; Costa FF; Lima CS
Leuk Lymphoma; 2006 Feb; 47(2):285-9. PubMed ID: 16321859
[TBL] [Abstract][Full Text] [Related]
33. Incidence of p53 and ras gene mutations in DMBA-induced rat leukemias.
Wei S; Kito K; Miyoshi A; Matsumoto S; Kauzi A; Aramoto T; Abe Y; Ueda N
J Exp Clin Cancer Res; 2002 Sep; 21(3):389-96. PubMed ID: 12385583
[TBL] [Abstract][Full Text] [Related]
34. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
Morgan TK; Zhao S; Chang KL; Haddix TL; Domanay E; Cornbleet PJ; Arber DA; Natkunam Y
Am J Clin Pathol; 2006 Oct; 126(4):545-51. PubMed ID: 16938662
[TBL] [Abstract][Full Text] [Related]
35. Multiple myeloma: current perspectives.
Slovak ML
Clin Lab Med; 2011 Dec; 31(4):699-724, x. PubMed ID: 22118745
[TBL] [Abstract][Full Text] [Related]
36. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
Hanamura I; Stewart JP; Huang Y; Zhan F; Santra M; Sawyer JR; Hollmig K; Zangarri M; Pineda-Roman M; van Rhee F; Cavallo F; Burington B; Crowley J; Tricot G; Barlogie B; Shaughnessy JD
Blood; 2006 Sep; 108(5):1724-32. PubMed ID: 16705089
[TBL] [Abstract][Full Text] [Related]
37. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
38. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
[TBL] [Abstract][Full Text] [Related]
39. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
40. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma.
Rasmussen T; Haaber J; Dahl IM; Knudsen LM; Kerndrup GB; Lodahl M; Johnsen HE; Kuehl M
Haematologica; 2010 Oct; 95(10):1730-7. PubMed ID: 20511669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
